John Ojeifo, M.D., Ph.D., M.B.A.
Center to Reduce Cancer Health Disparities
National Cancer Institute
9609 Medical Center Drive, MSC 9746
Sixth Floor, West Tower, 6W256
Bethesda, MD 20852
phone: (240) 276-6186
fax: (240) 276-7862
John O. Ojeifo, M.D., Ph.D., M.B.A., is a Program Director in the Diversity Training Branch for the Center to Reduce Cancer Health Disparities. Dr. Ojeifo serves as the Project Officer and Program Director for career development (K01, K08 & K23) program. He provides technical and scientific expertise and grants program administration guidance to career development grantee applicants/recipients, and takes a leadership role in conceptualizing, planning, developing, implementing, managing, and evaluating research programs for career development of minority grantee applicants/recipients.
Prior to his appointment at the National Cancer Institute, Dr. Ojeifo worked as a cancer biologist. He has a broad range of research interests including, endothelial cell biology, stem cells biology, tumor angiogenesis, genetics, experimental therapeutics, tumor immunology and immunotherapy, cancer health disparities, and holistic medicine. His most recent work investigated the therapeutic efficacy and safety of combined gene therapy for metastatic breast cancer and the contribution of endothelial progenitor cells to vasculatures in human and mouse breast tumors.
Dr. Ojeifo received his M.B.B.S. degree (M.D. equivalent) from the College of Medicine of the University of Lagos, Nigeria in 1979. After practicing clinical medicine for several years in Nigeria, he moved to Georgetown University, Washington, DC where he obtained his Ph.D. in human anatomy and cell biology in 1990 and also did postdoctoral work in gene therapy at the Lombardi Comprehensive Cancer Center. He subsequently joined the University as a member of faculty of the Medical Center in 1994. Dr. Ojeifo also holds an M.B.A. degree in Health Care Management from the University of Phoenix (2006).
Selected Publications and Presentations
Chizea JP, Vernon D, Williams E, Johnson M, and. Ojeifo JO. (2008). Endothelial Progenitor Cells Significantly Contribute to Vasculatures in Human and Mouse Breast Tumors. The Open Hematology Journal, 1: 30-62
“Communicating Your Science: Perspective of a Reviewer” 2008 NCI/Center to Reduce Cancer Health Disparities 2008 Summit and Professional Development Workshop. Rockville, MD. July 14-16, 2008.
Xiaming Ju, Sanjay Katiyar, Chenguang Wang, Manran Liu, Xuanmao Jiao, Jie Zhou, Jacob Turner, Michael p. Lisanti, Robert G. Russell, Susette Mueller, John Ojeifo, WS. Chen, Nissam Hay, and Richard G. Pestell. (2007). Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci USA 104: 7438-7443.
“Components of Successful Grant Application: Perspective of a Grantee” NCI/Center to Reduce Cancer Health Disparities 2007 Summit and Professional Development Workshop. Gaithersburg, MD. May 7-8, 2007
“Endothelial cell-based targeting of invasive prostate cancer in a murine model” Georgetown University, Washington, DC, 2006
Fricke ST, Rodriguez O, VanMeter J, Dettin L, Casimiro M, Chien C, Newell T, Johnson K, Ileva L, Ojeifo J, Johnson M, and Albanese C. (2006) .In vivo Magnetic Resonance Volumetric and Spectroscopy Analysis of Mouse Prostate Cancer Models. Prostate. 66 (7):708-717.
“De novo endothelial cells, tumor blood supply and Cancer progression". Department of Cell Biology, Georgetown University, Washington, DC. 2005.
“Contribution of bone-marrow derived endothelial Cells to tumor blood supply.” M.D. Anderson Cancer Center, University of Texas, Houston, Texas. 2005.
Isenberg JI, Shilpashree Vinod-Kumar, White, GD, and Ojeifo JO. (2005). Hematopoietic Stem Cells Mobilization and Immune Response in Tumor Bearing Mice. Annals of Plastic Surgery, Vol. 52 (5), pp 523-530 and Vol. 55 (3), September 2005, p. 249.
Ojeifo JO, Wu, A.G., Herscowitz H.B., Meehan, K.R. (2003). Phenotypic and Immunologic Characteristics of Docetaxel-Mobilized Peripheral blood stem cells in Mice. J. Hematotherapy and Stem Cell Research 12: 189-197
“Endothelial Cell-based Gene Therapy of Metastatic Breast Cancer” Howard University Washington, DC, 2004.
“Endothelial Cell-based Gene Therapy” Georgetown University, Washington, DC, 2000.